Israel’s Protalix Biotherepeutics reported good results in its trials of its PRX-102 treatment for the genetic disease Fabry’s.  Even a low dosage had an average 78.8% decrease in the effect of pain on the patients’ functioning.

https://www.globes.co.il/en/article-protalix-jumps-on-positive-fabry-disease-trial-results-1000999518